Clinical Research

Individuals living with type 2 diabetes were enrolled in a program that provided the Dexcom G6 system and BlueStar to understand how engagement with the combined solution influenced the Association of Diabetes Care and Education Specialists’ 7 self-care (ADCES7) behaviors. Data showed that those who continuously used real-time CGM (rtCGM) engaged with the app 13% more than those who used it intermittently. In addition, this data showed that engagement with a digital solution, coupled with continuous rtCGM use, can help individuals with T2D — even those who are not prescribed insulin — improve adherence to ADCES7 behaviors.

Welldoc partnered with The Montana Diabetes Digital Health Learning Network (MDDHLN) to introduce the BlueStar app was into their Diabetes Care and Education Specialist (DCES) program. People with diabetes (PWD) who engaged with the app saw A1C improvement after 6 months of use and 87% of the population with an A1C of 8 or less demonstrated positive health outcomes. The average persistence in app use is 18 months with 20% of people still using the app at 2 years. In addition to this sustained engagement, over 53% of the participants sent the SMART Visit ReportTM to their DCES at least once per month showing ongoing support for DCES’ between office visits. This data shows that using a digital health solution can not only support diabetes education for PWD between office visits but that use also creates value in the information and feedback they receive, thus generating continued engagement.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the presentation of data at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), evaluating how the combination of real-time CGM (rtCGM) with a digital health solution impacts glucose control for individuals with Type 2 diabetes not treated with insulin. For all participants and subgroups that were examined, the time in range (TIR) and glucose management indicator (GMI) improved significantly, demonstrating that a combined CGM and digital therapeutic solution has the potential to improve Type 2 diabetes management and glycemic control.

This collaborative study, with Dr. Edwin Fisher PhD of University of North Carolina, Peers for Progress and Vanguard Medical Group, assess the effectiveness of the Welldoc solution and peer support in providing health management and education for adults with Type 2 Diabetes.

Truven Health Analytics, part of IBM Watson Health, conducted an analysis of commercial and Medicare consumers within the MarketScan databases for Welldoc. The research findings show Welldoc's ability to help lower and control A1C and generate savings per user per month.

Health plans must find a scalable solution that reduces healthcare use and costs among those with chronic conditions. This study from Aetna/CVS Health, Welldoc, and LifeScan explores health plan strategies that take advantage of digital health relative to outcomes.